We showed that mutations in POLE (OR = 0.9690, 95% CI = 0.9422–0.9959, p value = 0.0243) and POLD1 (OR = 0.9573, 95% CI = 0.9223–0.9925, p value = 0.0177) were both more prevalent in younger endometrial cancer patients (Fig. 4d). This evidence concerns the gene POLE and endometrial cancer.